Cepheid Inc (Cepheid), a subsidiary of Danaher Corp, is a molecular diagnostic company that develops, manufactures, and markets molecular systems and conducts tests for clinical and non-clinical markets. The company offers in vitro diagnostic tests for health care-associated infections, critical infectious diseases, sexual health, virology, oncology and genetics; molecular diagnostic systems; and reagents and parts. Cepheid distributes its products directly and through a network of distributors present across the Americas, Asia, Europe, Africa and the Middle East. The company also offers various services such as maintenance, software updates, repair, and support among others. Cepheid is headquartered in Sunnyvale, California, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Cepheid Inc
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Cepheid Inc Company Overview
Cepheid Inc Company Snapshot
Cepheid Inc Pipeline Products and Ongoing Clinical Trials Overview
Cepheid Inc – Pipeline Analysis Overview
Business Description
Cepheid Inc - Key Facts
Cepheid Inc - Major Products and Services
Cepheid Inc Pipeline Products by Development Stage
Cepheid Inc Ongoing Clinical Trials by Trial Status
Table 20: GeneXpert Omni - HIV-1 Qualitative Test - Product Status
Table 21: GeneXpert Omni - HIV-1 Qualitative Test - Product Description
Table 22: GeneXpert Omni - HIV-1 Viral Load Test - Product Status
Table 23: GeneXpert Omni - HIV-1 Viral Load Test - Product Description
Table 24: GeneXpert Omni - MTB/RIF - Product Status
Table 25: GeneXpert Omni - MTB/RIF - Product Description
Table 26: GeneXpert Omni - MTB/RIF - Study of GeneXpert MTB/RIF Versus the Routine Methods for Detection of Mycobactrium Tuberculosis
Table 27: GeneXpert Omni - Xpert CT/NG - Product Status
Table 28: GeneXpert Omni - Xpert CT/NG - Product Description
Table 29: GeneXpert Omni - Xpert CT/NG - Randomized Controlled Trial in Nepal: Introducing Point-of-care Tests and Identifying Barriers to Reduce Antibiotics for Vaginal Discharge
Table 30: GeneXpert Omni - Xpert HPV - Product Status
Table 31: GeneXpert Omni - Xpert HPV - Product Description
Table 32: GeneXpert Omni - Xpert HPV CLIA Waived - Product Status
Table 36: GeneXpert Omni - Xpert MTB/RIF Ultra - Cepheid GeneXpertOmni Combined with the Xpert MTB/RIF Ultra (Omni/Ultra) for Detection of Tuberculosis and Rifampicin Resistance in Adults with Presumptive Pulmonary Tuberculosis at Primary-level Diagnostic Centres in Tanzania and Mozambique: a Pragmatic, Cluster-randomized Controlled Trial
Table 37: GeneXpert Omni - Xpress CT/NG CW - Product Status